Arthneeti
All Q2 FY26 results →
AE

Aprameya Engineering Ltd

Q2 FY26

Aprameya Engineering Q2 FY26 investor presentation: Revenue & Margins

Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹88
Market cap₹168 Cr
P/E33.4
Updated16 Oct 2026
Read4 min read

Based on Aprameya Engineering Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. H1FY26 EBITDA: Rs 112.1 Mn, margin 26%, a 1123% YoY increase (from -11.0 Mn and -11% margin in H1FY25).

From Aprameya Engineering Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

  • H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25.
  • Total Income for H1FY26: Rs 423.3 Mn, up 343% YoY.
  • EBITDA for H1FY26: Rs 112.1 Mn, up 1123% YoY.
  • PAT for H1FY26: Rs 67.6 Mn, up 492% YoY.
  • Revenue Mix H1FY26: 88% Turnkey Project, 12% Medical Equipment Solutions.
  • Executed Modular OT projects (~Rs 270 Mn) and medical equipment deliveries (~Rs 25 Mn) during the period.
  • Outlook:
  • Targeting 20–25% CAGR over the next 3 years in overall revenue.
  • Order book to scale to Rs 300–350 Cr in 3 years.
  • Active bid pipeline of Rs 190–200 Cr.
  • Recurring revenue from CAMC, consumables, spares targeted at Rs 12–15 Cr annually by FY29.

2 more points from Aprameya Engineering Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Aprameya Engineering Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Aprameya plans to launch a manufacturing facility by Q4 FY27 to support MedTech product scale-up (Page 8).
  • The facility aims to enable 200-250 bps margin accretion (Page 8).
  • A dedicated R&D team will be established post-facility launch for faster product development, prototyping, and clinical validation (Page 8).
  • Until the facility becomes operational, the company will rely on contract manufacturing to ensure early market entry (Page 5).

2 more points from Aprameya Engineering Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Fundraising & Capital Structure

See what Aprameya Engineering Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

- The investor presentation reports an order book expected to scale to Rs 300-350 Crore over the next 3 years. (Page 8) - The current active bid pipeline stands at Rs 190-200 Crore. (Page 8) No specific mention of order inflow or pending orders beyond these figures is provided in the presentation.

Continue your research

What Aprameya Enginee's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • Vaidya Sane (Q2 FY26)

    Ongoing construction and CAPEX of about INR 25-30 crores for capacity expansion at Khopoli and Nagpur hospitals. Key concall takeaways from Vaidya Sane's Q2…

  • Earkart (Q2 FY26)

    Earkart has already secured government orders worth approximately ₹9 crores in the current fiscal year (Page 8, 7th excerpt). Key concall takeaways from…

  • QMS Medical Allied Services Ltd (Q2 FY26)

    The only related transaction noted is the recent acquisition of Saarathi increasing stake from 51% to 76%, but no fundraising details were shared with respect…

  • Poly Medicure Ltd (Q2 FY26)

    1,090 crores, representing over 25% growth compared to H1 (Rs. Key concall takeaways from Poly Medicure's Q2 FY26 earnings call — and how it ranks against…

Compare:vs Molbio Diagnostivs Poly Medicure Ltdvs Q-Line Biotech

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Aprameya Engineering Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Aprameya Engineering Ltd Q2 FY26 results?

H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. H1FY26 EBITDA: Rs 112.1 Mn, margin 26%, a 1123% YoY increase (from -11.0 Mn and -11% margin in H1FY25).

What is Aprameya Engineering Ltd share price analysis?

Aprameya Engineering Ltd currently shows a neutral. The stock trades at a P/E of 33.4 with a market cap of ₹168 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aprameya Engineering Ltd planning capital expenditure?

Aprameya plans to launch a manufacturing facility by Q4 FY27 to support MedTech product scale-up (Page 8).

Keep Aprameya Engineering Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.